Anastrozole 1 - Somatrop-Lab

Finally got approval  by the FDA at the end of 1995. Anastrozole in many countries is  recognized as “arimidex”  is a third generation aromatase inhibitor and was produced by a company  “Zeneca Pharmaceuticals”. Main purpose is to effectively block the aromatase enzyme, leading to a lower level  in estrogen production, which is crucial for the growth of certain breast cancers. This drug quickly became a preferred option in the treatment of hormone sensitive breast cancer, especially for people  who had previously been treated with tamoxifen.

Disclaimer: Information provided it this page is for general information only and does not substitute for professional medical advice.

For detailed information about Anastrozole 1 by Somatrop-Lab, consult with your doctor or healthcare professional.